Steven E. Vogl

1.8k total citations
55 papers, 1.4k citations indexed

About

Steven E. Vogl is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Steven E. Vogl has authored 55 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 20 papers in Surgery and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Steven E. Vogl's work include Ovarian cancer diagnosis and treatment (13 papers), Lung Cancer Treatments and Mutations (8 papers) and Head and Neck Cancer Studies (7 papers). Steven E. Vogl is often cited by papers focused on Ovarian cancer diagnosis and treatment (13 papers), Lung Cancer Treatments and Mutations (8 papers) and Head and Neck Cancer Studies (7 papers). Steven E. Vogl collaborates with scholars based in United States, United Kingdom and South Africa. Steven E. Vogl's co-authors include Barry H. Kaplan, Edward S. Greenwald, Richard H. Creech, David S. Ettinger, John C. Ruckdeschel, Bernard A. Mason, R Joss, Dianne M. Finkelstein, Vicki Seltzer and Fernando Camacho and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Cancer.

In The Last Decade

Steven E. Vogl

50 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steven E. Vogl United States 21 749 554 458 276 250 55 1.4k
Hideo Niibe Japan 24 440 0.6× 787 1.4× 391 0.9× 92 0.3× 165 0.7× 143 1.7k
Naveen Faridi Pakistan 24 570 0.8× 265 0.5× 291 0.6× 90 0.3× 110 0.4× 85 1.4k
J. F. Pringle Canada 18 480 0.6× 310 0.6× 363 0.8× 355 1.3× 29 0.1× 22 1.3k
Ірина Давиденко United States 16 807 1.1× 583 1.1× 284 0.6× 63 0.2× 242 1.0× 33 1.6k
Sylvie Isaac France 21 586 0.8× 678 1.2× 738 1.6× 367 1.3× 22 0.1× 51 2.0k
Anders Lindgren Sweden 19 695 0.9× 386 0.7× 547 1.2× 188 0.7× 12 0.0× 32 1.7k
Charalambos Kouroussis Greece 18 1.0k 1.4× 752 1.4× 143 0.3× 48 0.2× 88 0.4× 49 1.5k
Enzo Maria Ruggeri Italy 22 681 0.9× 535 1.0× 354 0.8× 36 0.1× 98 0.4× 103 1.4k
Melanie Mackean United Kingdom 20 873 1.2× 469 0.8× 236 0.5× 444 1.6× 20 0.1× 48 1.7k
Sharadah Essapen United Kingdom 16 799 1.1× 498 0.9× 1.1k 2.5× 943 3.4× 23 0.1× 33 2.1k

Countries citing papers authored by Steven E. Vogl

Since Specialization
Citations

This map shows the geographic impact of Steven E. Vogl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven E. Vogl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven E. Vogl more than expected).

Fields of papers citing papers by Steven E. Vogl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven E. Vogl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven E. Vogl. The network helps show where Steven E. Vogl may publish in the future.

Co-authorship network of co-authors of Steven E. Vogl

This figure shows the co-authorship network connecting the top 25 collaborators of Steven E. Vogl. A scholar is included among the top collaborators of Steven E. Vogl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven E. Vogl. Steven E. Vogl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yahanda, Alexander T., Steven E. Vogl, Jan D. Galla, et al.. (2025). The Lower Lordotic Arch Is a Driver of Pelvic Positioning and Inflection Point Migration in Adult Spinal Deformity. Spine. 51(1). 34–42.
2.
Vogl, Steven E.. (2017). Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment. Breast Cancer Research and Treatment. 166(1). 1–13. 5 indexed citations
3.
Vogl, Steven E., et al.. (2012). Characterization of patients who received further adjuvant endocrine therapy after 5 years of aromatase inhibitors (AIs): NCIC CTG MA 27.. Journal of Clinical Oncology. 30(15_suppl). e11005–e11005.
4.
5.
Wiernik, Peter H., Edward S. Greenwald, Harrison Ball, James A. Young, & Steven E. Vogl. (1998). High-Dose Megestrol Acetate in the Treatment of Patients With Ovarian Cancer Who Have Undergone Previous Treatment. American Journal of Clinical Oncology. 21(6). 565–567. 14 indexed citations
6.
Wiernik, P H, Beow Y. Yeap, Steven E. Vogl, et al.. (1992). Hexamethylmelamine and Low or Moderate Dose Cisplatin With or Without Pyridoxine for Treatment of Advanced Ovarian Carcinoma: A Study of the Eastern Cooperative Oncology Group. Cancer Investigation. 10(1). 1–9. 50 indexed citations
7.
Grem, Jean L., Peter J. O’Dwyer, Paul Elson, et al.. (1991). Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.. Journal of Clinical Oncology. 9(10). 1793–1800. 13 indexed citations
8.
Vogl, Steven E., et al.. (1991). Myeloma of the head of the pancreas. A case report. Cancer. 67(3). 681–683. 21 indexed citations
9.
Trump, Donald L., John C. Marsh, Larry K. Kvols, et al.. (1990). A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. Investigational New Drugs. 8(S1). S91–S94. 31 indexed citations
10.
Young, James A., et al.. (1989). Intraperitoneal Cisplatin with Intravenous Cyclophosphamide and Doxorubicin for Previously Untreated Stage III and IV Ovarian Carcinoma. Cancer Investigation. 7(6). 565–570. 4 indexed citations
11.
12.
Seltzer, Vicki, et al.. (1984). Doxorubicin and cisplatin in the treatment of advanced mixed mesodermal uterine sarcoma.. PubMed. 68(11). 1389–90. 12 indexed citations
13.
Goldfarb, Johanna, et al.. (1984). Fatal Cryptosporidiosis Complicating Kaposi’s Sarcoma in an Immunocompromised Man. The American Journal of the Medical Sciences. 287(2). 47–48. 6 indexed citations
14.
Seltzer, Vicki, Steven E. Vogl, & Barry H. Kaplan. (1984). Adriamycin and cis-diamminedichloroplatinum in the treatment of metastatic endometrial adenocarcinoma. Gynecologic Oncology. 19(3). 308–313. 17 indexed citations
15.
Vogl, Steven E., et al.. (1983). Tumor Mapping: New Rationales, Adjusted Techniques, Expanded Applications. The Laryngoscope. 93(10). 1285–1286.
16.
Vogl, Steven E., et al.. (1982). Sequential chemotherapy of advanced colorectal cancer with standard or high‐dose methotrexate followed by 5‐fluorouracil. Medical and Pediatric Oncology. 10(2). 145–149. 10 indexed citations
17.
Vogl, Steven E., et al.. (1981). Safe and effective two-hour outpatient regimen of hydration and diuresis for the administration of cis-diamminedichloroplatinum (II). European Journal of Cancer (1965). 17(3). 345–350. 15 indexed citations
18.
Vogl, Steven E., Richard J. Lanham, & Barry H. Kaplan. (1980). Combination Chemotherapy of Advanced Colorectal Cancer with Triazinate and ICRF-159 after Failure of 5-Fluorouracil. Oncology. 37(5). 314–315. 3 indexed citations
19.
Vogl, Steven E., et al.. (1980). Toxicity of Cis-diamminedichloroplatinum II given in a two-hour outpatient regimen of diuresis and hydration. Cancer. 45(1). 11–15. 57 indexed citations
20.
Vogl, Steven E., Takao Ohnuma, Marjorie Perloff, & James F. Holland. (1976). Combination chemotherapy with adriamycin andcis-diamminedichloroplatinum in patients with neoplastic diseases. Cancer. 38(1). 21–26. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hideo Niibe Breakdown of academic impact, for papers by Naveen Faridi Breakdown of academic impact, for papers by J. F. Pringle Breakdown of academic impact, for papers by Ірина Давиденко Breakdown of academic impact, for papers by Sylvie Isaac Breakdown of academic impact, for papers by Anders Lindgren Breakdown of academic impact, for papers by Charalambos Kouroussis Breakdown of academic impact, for papers by Enzo Maria Ruggeri Breakdown of academic impact, for papers by Melanie Mackean Breakdown of academic impact, for papers by Sharadah Essapen
Rankless by CCL
2026